TY - JOUR
T1 - Joint-specific risk of impaired function in fibrodysplasia ossificans progressiva (FOP)
AU - Pignolo, Robert J.
AU - Durbin-Johnson, Blythe P.
AU - Rocke, David M.
AU - Kaplan, Frederick S.
N1 - Funding Information:
This work was supported in part by the International Fibrodysplasia Ossificans Progressiva Association (IFOPA), the Center for Research in FOP and Related Disorders at the University of Pennsylvania Perelman School of Medicine, the Ian Cali Endowment for FOP Research, the Whitney Weldon Endowment for FOP Research, and the Isaac and Rose Nassau Professorship of Orthopaedic Molecular Medicine (to FSK); the Ian Cali Distinguished Clinician-Scientist at the Center for Research in FOP and Related Disorders at the University of Pennsylvania, the Robert and Arlene Kogod Professorship in Geriatric Medicine at the Mayo Clinic, and the Radiant Hope Foundation (to RJP); and the National Center for Advancing Translational Sciences, National Institutes of Health UL1 TR001860 and the University of California Davis School of Medicine (to DMR).
Funding Information:
This work was supported in part by the International Fibrodysplasia Ossificans Progressiva Association (IFOPA) , the Center for Research in FOP and Related Disorders at the University of Pennsylvania Perelman School of Medicine, the Ian Cali Endowment for FOP Research , the Whitney Weldon Endowment for FOP Research , and the Isaac and Rose Nassau Professorship of Orthopaedic Molecular Medicine (to FSK); the Ian Cali Distinguished Clinician-Scientist at the Center for Research in FOP and Related Disorders at the University of Pennsylvania, the Robert and Arlene Kogod Professorship in Geriatric Medicine at the Mayo Clinic, and the Radiant Hope Foundation (to RJP); and the National Center for Advancing Translational Sciences , National Institutes of Health UL1 TR001860 and the University of California Davis School of Medicine (to DMR).
Publisher Copyright:
© 2017 Elsevier Inc.
PY - 2018/4
Y1 - 2018/4
N2 - Background: Fibrodysplasia ossificans progressiva (FOP) causes progressive disability due to heterotopic ossification from episodic flare-ups. Using data from 500 FOP patients (representing 63% of all known patients world-wide), age- and joint-specific risks of new joint involvement were estimated using parametric and nonparametric statistical methods. Results: Compared to data from a 1994 survey of 44 individuals with FOP, our current estimates of age- and joint-specific risks of new joint involvement are more accurate (narrower confidence limits), based on a wider range of ages, and have less bias due to its greater comprehensiveness (captures over three-fifths of the known FOP patients worldwide). For the neck, chest, abdomen, and upper back, the estimated hazard decreases over time. For the jaw, lower back, shoulder, elbow, wrist, fingers, hip, knee, ankle, and foot, the estimated hazard increases initially then either plateaus or decreases. At any given time and for any anatomic site, the data indicate which joints are at risk. Conclusions: This study of approximately 63% of the world's known population of FOP patients provides a refined estimate of risk for new involvement at any joint at any age, as well as the proportion of patients with uninvolved joints at any age. Importantly, these joint-specific survival curves can be used to facilitate clinical trial design and to determine if potential treatments can modify the predicted trajectory of progressive joint dysfunction.
AB - Background: Fibrodysplasia ossificans progressiva (FOP) causes progressive disability due to heterotopic ossification from episodic flare-ups. Using data from 500 FOP patients (representing 63% of all known patients world-wide), age- and joint-specific risks of new joint involvement were estimated using parametric and nonparametric statistical methods. Results: Compared to data from a 1994 survey of 44 individuals with FOP, our current estimates of age- and joint-specific risks of new joint involvement are more accurate (narrower confidence limits), based on a wider range of ages, and have less bias due to its greater comprehensiveness (captures over three-fifths of the known FOP patients worldwide). For the neck, chest, abdomen, and upper back, the estimated hazard decreases over time. For the jaw, lower back, shoulder, elbow, wrist, fingers, hip, knee, ankle, and foot, the estimated hazard increases initially then either plateaus or decreases. At any given time and for any anatomic site, the data indicate which joints are at risk. Conclusions: This study of approximately 63% of the world's known population of FOP patients provides a refined estimate of risk for new involvement at any joint at any age, as well as the proportion of patients with uninvolved joints at any age. Importantly, these joint-specific survival curves can be used to facilitate clinical trial design and to determine if potential treatments can modify the predicted trajectory of progressive joint dysfunction.
KW - ACVR1
KW - Bone morphogenetic protein signaling
KW - Fibrodysplasia ossificans progressiva
KW - Heterotopic ossification
KW - Joint survival
KW - Risk
UR - http://www.scopus.com/inward/record.url?scp=85027407430&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85027407430&partnerID=8YFLogxK
U2 - 10.1016/j.bone.2017.06.009
DO - 10.1016/j.bone.2017.06.009
M3 - Article
C2 - 28627475
AN - SCOPUS:85027407430
SN - 8756-3282
VL - 109
SP - 124
EP - 133
JO - Bone
JF - Bone
ER -